Caris Life Sciences, Inc. <CAI.O>: UBS Initiates Coverage With Neutral Rating And Target Price $28
CAI•Related News
Gossamer Bio announces 1-for-80 reverse stock split
GOSS•
Alpha Modus stockholders back PIPE deal issuing 51,621,560 shares, warrants for 51,621,560 more at USD 4.36 each
AMOD•
Pacific Biosciences of California, Inc. <PACB.O>: UBS cuts target price to $1.35 from $1.5
PACB•
Baker Hughes raises annual forecasts after Chart acquisition
BKR•
Bruker Corporation <BRKR.O>: UBS raises target price to $65 from $45
BRKR•